Search

Daclizumab

On 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection … Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by

HY10275

This dual-acting receptor activity and the lack of affinity for undesired off- target receptors are thought to account for the compounds excellent efficacy and tolerability profile. … HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep.

Floxuridine

Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. … It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.

Sapropterin

Sapropterin (tetrahydrobiopterin or BH4) is a cofactor in the synthesis of nitric oxide. It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa ...

Veru-111

VERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360.

Hyoscyamine

[A228713] Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimuscarinic properties.

Interferon alfacon-1

Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1.

Biguanide

Biguanide has been investigated for the treatment of Diabetes Mellitus.

Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen

DaxibotulinumtoxinA

[L47865] On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. … [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.